



an Open Access Journal by MDPI

Recent Advances in Modulating Mitophagy with Novel Drugs/Compounds

Guest Editor:

Dr. Mingchong Yang

Genetics and Genome Sciences,
University of Connecticut Health
Center, Farmington, CT, USA

Deadline for manuscript
submissions:

5 February 2025

Message from the Guest Editor

The heart is beating all the time, and the demand for energy is very high, so mitochondrial damage can cause serious heart disease. Mitochondria are in a dynamic balance of continuous division and fusion. Damaged mitochondria are engulfed by lysosomes and degraded; this process was named mitophagy. Mitophagy provides an important guarantee for mitochondrial quality control. Thus, looking for solutions to heart disease from the perspective of mitophagy will be an important direction of future research for cardiomyopathy, including (but not limited to) searching for novel drugs or compounds that modulate the mitophagy process, exploring how drugs treat heart disease by affecting the mitophagy mechanism, and investigating how drug delivery can improve the treatment of heart disease. This Special Issue on “Recent Advances in Modulating Mitophagy with Novel Drugs/Compounds” aims to provide up-to-date insights into the remarkable complexity of mitophagy and on its dysregulation in the context of many different kinds of heart diseases. We look forward to receiving your contributions.



mdpi.com/si/213501

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com